2015
DOI: 10.4155/fso.15.10
|View full text |Cite
|
Sign up to set email alerts
|

Biotechnology Landscape in Cancer Drug Discovery

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
3
0

Year Published

2016
2016
2022
2022

Publication Types

Select...
2
1

Relationship

1
2

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 18 publications
0
3
0
Order By: Relevance
“…It is therefore beneficial to dissect effects experimentally by cell-selective agents. [294][295][296] Furthermore, exploration of molecular concepts cannot be covered by biopharmaceutical industries, due to the fact that the concepts address essentially basic research. 20,289,290 What is the technical maturity of the concepts of CQ use against tumors?…”
Section: Feasibility Of Treating Malignant Tumors With Cq: Strengths mentioning
confidence: 99%
See 1 more Smart Citation
“…It is therefore beneficial to dissect effects experimentally by cell-selective agents. [294][295][296] Furthermore, exploration of molecular concepts cannot be covered by biopharmaceutical industries, due to the fact that the concepts address essentially basic research. 20,289,290 What is the technical maturity of the concepts of CQ use against tumors?…”
Section: Feasibility Of Treating Malignant Tumors With Cq: Strengths mentioning
confidence: 99%
“…292,293 In contrast to genomics, there does not seem to be a major change of research support in sight for high-capacity molecular innovation. [294][295][296] Furthermore, exploration of molecular concepts cannot be covered by biopharmaceutical industries, due to the fact that the concepts address essentially basic research. Research priorities, however, can change in the public sector.…”
Section: Feasibility Of Treating Malignant Tumors With Cq: Strengths mentioning
confidence: 99%
“…In the last years we are facing the development of a myriad of technologies searching for the “golden biomarker.” The omics family is constantly adding a new member, such as genomics, proteomics, peptidomics, newer ones, epigenomics, transcriptomics, metabolomics, lipidomics, pharmacogenomics, interactomics, and chronemics, just mentioning a few [1]. …”
mentioning
confidence: 99%